Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novel erythropoiesis stimulating protein (NESP): Began Phase II testing

(Regulatory, B5; Clinical results, B8)

Amgen Inc. (AMGN),

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE